Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Sanofi

Status and phase: Completed; Phase 3

Conditions: Arthroplasty, Replacement, Hip

Treatments: Drug: Enoxaparin sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00349180

EFC6770

Details and patient eligibility

About

This study is performed to confirm the optimal dose for THR (total hip replacement).

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing elective primary THR (total hip replacement) surgery

Exclusion criteria

• Patient with risk of clinical significant bleeding

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind